Baricitinib

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Covid19

Conditions

Covid19, Corona Virus Infection

Trial Timeline

Dec 21, 2021 → Nov 4, 2024

NCT ID

NCT05074420

About Baricitinib

Baricitinib is a phase 3 stage product being developed by Eli Lilly for Covid19. The current trial status is terminated. This product is registered under clinical trial identifier NCT05074420. Target conditions include Covid19, Corona Virus Infection.

What happened to similar drugs?

4 of 15 similar drugs in Covid19 were approved

Approved (4) Terminated (4) Active (9)

✅Icosapent ethylAmarin CorporationApproved

✅bamlanivimabEli LillyApproved

✅COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)SanofiApproved

✅Moderna mRNA-1273 COVID-19 vaccine + Pfizer BNT162b2 COVID-19 vaccineAllergy TherapeuticsApproved

❌AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3

🔄LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3

🔄Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01724580	Pre-clinical	Completed	—	—	Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)
NCT06797310	Phase 2	Recruiting	Jan 23, 2025	Dec 31, 2026	Alopecia Areata
NCT05074420	Phase 3	Terminated	Dec 21, 2021	Nov 4, 2024	Covid19
NCT04517253	Phase 2/3	Terminated	Oct 27, 2020	Nov 28, 2024	Nakajo-Nishimura Syndrome
NCT03921554	Phase 2	Completed	Jun 3, 2019	Mar 25, 2024	Aicardi Goutieres Syndrome
NCT03773965	Phase 3	Recruiting	Apr 5, 2019	Jul 1, 2031	Juvenile Idiopathic Arthritis
NCT03559270	Phase 3	Terminated	Jun 27, 2018	Jun 13, 2022	Atopic Dermatitis
NCT03026504	Phase 2	Completed	Mar 9, 2017	Apr 12, 2021	Arteritis, Giant Cell
NCT02263911	Phase 1	Completed	Nov 1, 2014	Dec 1, 2014	Healthy Participants
NCT01870388	Phase 1	Completed	Jun 1, 2013	Jul 1, 2013	Liver Diseases

Competing Products

20 competing products in Covid19

See all competitors

Product	Company	Stage	Hype Score
AVIGAN + Placebo Comparator	Dr. Reddy's Laboratories	Phase 3	29
Favipiravir + Nitazoxanide	Strides Pharma	Phase 2	35
Icosapent ethyl	Amarin Corporation	Approved	25
GX-03 + Petrolatum ointment	Turn Therapeutics	Phase 2	25
Cytotoxic T Lymphocytes	Tevogen Bio	Phase 1	19
DS-5670a + Placebo	Daiichi Sankyo	Phase 1/2	32
Pegylated Interferon-α2b	Zydus Lifesciences	Phase 2	27
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814	Eli Lilly	Phase 3	40
bamlanivimab	Eli Lilly	Approved	35
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222	AstraZeneca	Phase 1	25
Sacubitril / Valsartan Oral Tablet [Entresto] + Placebo	Novartis	Phase 1/2	32
Pirfenidone	Roche	Pre-clinical	26
Remdesivir + Remdesivir Placebo + Corticosteroid	Gilead Sciences	Phase 3	40
Remdesivir	Gilead Sciences	Pre-clinical	26
Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + Corticosteroid	Gilead Sciences	Phase 3	40
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)	Pfizer	Phase 3	36
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine	Pfizer	Pre-clinical	26
Tofacitinib 10 mg + Placebo	Pfizer	Phase 3	40
BNT162b2	Pfizer	Phase 2	35
Anakinra + 0.9% Saline	Swedish Orphan Biovitrum	Phase 2	27